Epitalon Cell-Line Measurements: qPCR, TRAP and C-Circle Records

Research use only. This article summarizes named cell experiments and does not provide medical, veterinary, dosing, administration, safety, or outcome guidance.

Study source and corrected figures

Al-Dulaimi et al. reported an Epitalon cell-line study in 21NT and BT474 breast-cancer cells, IBR.3 fibroblasts, and HMEC epithelial cells [1]. The authors compared Epitalon experimental groups with untreated baseline controls and used DNA, RNA, and protein-derived measurements. A published correction states that the wrong versions of Figures 1, 2, and 3 appeared in the original article and supplies the corrected figures [2]. The figure-based observations below are therefore limited to the corrected figure set.

The correction identifies the affected figures as the telomere-length, hTERT/telomerase, and ALT/PML-body figure groups [2]. It replaces the figures rather than creating a separate cell experiment. This article does not reproduce figure values or use them outside the authors’ named comparison groups; it retains only the corrected source’s cell systems, assay types, controls, and qualitative conclusions.

The source uses the name Epitalon. Its introduction calls the peptide a tetrapeptide, AEDG, and states that it is also known as Epithalon. PubChem lists CID 219042 under the title Epitalon [3]. These are terminology records. They do not establish that a catalogue item and the material in the paper have the same identity, composition, or batch history.

Cell systems and comparison groups

The paper distinguishes two breast-cancer cell lines, 21NT and BT474, from IBR.3 fibroblasts and HMEC epithelial cells [1]. It also uses PC3-hTERT as a telomerase-related reference material and U2OS as an ALT-positive reference control in the relevant assays. These named systems are not interchangeable. A result in 21NT is an observation in the authors’ 21NT comparison, not a result for BT474, IBR.3, HMEC, another cell line, or a catalogue material.

For the Epitalon-versus-untreated comparisons, the authors extracted DNA to estimate telomere length, RNA to measure hTERT mRNA, and protein for telomerase activity measurement [1]. They used qPCR for telomere-length estimation and RNA expression, the telomere-repeat-amplification protocol (TRAP) for telomerase activity, and the C-circle assay for ALT activity. Immunofluorescence of PML bodies provided an additional ALT-associated observation in the stated cancer-cell comparisons.

Telomere-length estimates by qPCR

For 21NT, BT474, IBR.3, and HMEC, the authors used qPCR with a telomeric standard and the single-copy gene 36B4 to calculate total telomere-length estimates [1]. In the corrected Figure 1 comparison, the authors report longer qPCR telomere-length estimates in their Epitalon groups than in the stated untreated controls for the cell systems shown. This is a source-attributed result from the paper’s experimental groups, not an analytical result for Epithalon 10mg or an expected outcome outside those cell cultures.

The paper itself states a measurement limitation: the qPCR method reports average telomere length across chromosomes. It does not show whether every chromosome changed by the same amount. That limitation belongs with the reported qPCR result. It also means the qPCR estimate is not interchangeable with the authors’ hTERT, TRAP, C-circle, or immunofluorescence measurements.

hTERT and telomerase measurements

For the same named cell systems, the authors used RT-qPCR to quantify hTERT mRNA and TRAP to quantify telomerase activity [1]. Figure 2 includes the cancer-cell comparisons for 21NT and BT474 and the normal-cell comparisons for IBR.3 and HMEC; PC3-hTERT supplied the reported telomerase-related reference control. The authors report hTERT mRNA increases in the stated Epitalon comparisons. They further report that telomerase activity did not show a significant increase in the cancer-cell comparisons, while the normal-cell comparisons showed increased telomerase activity in the authors’ reported conditions.

These are separate readouts. The paper’s hTERT mRNA observation does not itself equal a TRAP activity measurement, and its TRAP activity observation does not establish a result for an untested cell system. The report also does not convert either measurement into a claim about a product batch, a person, or an animal.

ALT and PML-body measurements

The authors used the C-circle assay to quantify ALT activity and included untreated cells and the U2OS ALT-positive reference control in the corrected Figure 3 comparison [1, 2]. They report increased ALT activity in their 21NT and BT474 Epitalon comparison groups relative to the stated untreated controls. For IBR.3 and HMEC, the authors report different ALT results from the cancer-cell comparisons. Those model-specific observations should remain with the named cell system rather than being combined into a single cellular conclusion.

For 21NT and BT474, the paper also used immunofluorescence to detect PML bodies and reported the PML-body observation alongside the cancer-cell ALT comparison [1, 2]. The C-circle and PML-body measurements are related but distinct methods. Neither one supplies the qPCR telomere estimate, hTERT expression value, or TRAP activity for another group.

Evidence boundary

PMID 40908429 supports the specific source record above: four named cell systems, Epitalon-versus-untreated comparisons, defined molecular assays, and the authors’ corrected figure-based conclusions. It does not provide a product certificate, purity value, stability result, or lot identifier for Epithalon 10mg. It does not report human or veterinary use, and no such use can be inferred from the cell data.

Epithalon and Epitalon: Cell-Line Source Scope and Documentation Review addresses the broader terminology and material-documentation boundary. This page is narrower: it identifies the qPCR, TRAP, C-circle, and PML-body measurements and the corrected figure record in PMID 40908429.